Pharmaceutical

Arrowhead and Sarepta link for rare genetic disease treatments

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.

Nov 27, 2024 - 06:00
Arrowhead and Sarepta link for rare genetic disease treatments
Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.
Read the original article

Tags:

Previous Article

Jazz’s HER2 Bispecific Gets FDA Green Light

Next Article

NHS rolls out monoclonal antibody treatment for rare bone disease  

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Private equity deals in pharmaceutical in China increas...

Jul 31, 2023

Q&A: Chronicling the failures of the U.S. response to Covid

Q&A: Chronicling the failures of the U.S. response to C...

Apr 25, 2023

Acceleron Pharma gets grant for treatment of spinal mus...

Apr 11, 2024